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Abstract
In recent years, antimicrobial drug resistance has become widespread and thus triggered
an ever-growing need for the development of new, efficacious drug treatments. As an
antimicrobial drug is developed, its mechanism of action is often identified before it
becomes a potential candidate for clinical use. One potential method for identifying
mechanism of action is chemical mutagenesis, in which induction of drug-resistant
populations is followed by whole-genome sequencing of several clonal isolates. The
subsequent observation of identical point mutations in the same gene across multiple
drug-resistant populations can indicate a likely molecular target. However, this technique
lacks the capacity to facilitate speedy and robust elucidation of the mechanism of action
of experimental compounds, indicating a need for improved methods to enhance the
efficiency of high-throughput drug target identification. In this work, a novel technique
utilizing double chemical mutagenesis was developed in order to quickly induce the high
levels of resistance indicative of specific resistance in the apicomplexan parasite
Toxoplasma gondii. This technique is being used to identify drug targets in experimental
compound, SW33, that has shown efficacy against T. gondii.
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Introduction
The microbial infections caused by bacteria, viruses, and parasites are a leading
cause of death worldwide [1,2]. Although there are currently a wide variety of treatments
for microbial infections, the widespread use of antimicrobial drugs has led to
unprecedented rates of resistance [3]. In fact, the World Health Organization has reported
that combating drug resistance is one of the most important aspects of maintaining global
public health [3]. During the drug development process, experimental compounds are
first tested to in vitro then in vivo to determine their capability of fighting infections. The
compounds that show efficacy in these conditions have the potential for clinical use.
However, before they can move to pre-clinical trials, the way they function inside the
cell, termed mechanism of action (MOA), is usually determined. It is important to
elucidate the MOA as it can demonstrate that an antimicrobial drug is nontoxic; ideal
drugs will target pathogens while leaving human cells unharmed. Additionally,
elucidating the MOA can provide insight into the best best way to modify compounds to
improve efficacy and ways to optimize combinational drug therapy.
The MOA of many antimicrobials is through the binding of a specific protein,
termed the drug target, which renders the protein inactive. One of the ways that microbes
develop resistance to drugs is through the development of mutations in the drug target
which prevent the antimicrobial compound from binding. One method to elucidate MOA
is through the utilization of this natural process. In the process of chemical mutagenesis, a
chemical mutagen is applied to a large number of microbes to induce a specific number
of mutations. An experimental compound is then applied to the mutant microbes at
various concentrations and resistant populations are clonally isolated. Next generation
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sequencing (NGS) is then performed and mutations in the same gene across several
resistant microbes indicates a potential drug target. The mutant allele is then transfected
into wild-type microbes and, if resistance is observed, it is likely the drug target has been
identified. Further tests can then be performed to verify the correct identification of the
drug target, including in silico drug-binding assays and cocrystallization of the protein
with bound drug.
A current problem with chemical mutagenesis is that often times only low levels
of resistance is observed. This can potentially lead to the false-identification of a drug
target because, during the acquisition of antimicrobial resistance, low levels of resistance
can be indicative of general fitness advantages while high resistance is generally
associated with mutations in the drug target. Thus, when attempting to identify mutations
in the gene encoding the drug target (as needed for MOA identification), it is ideal to
demonstrate high levels of resistance. In order to do this, a novel method of double
chemical mutagenesis was developed.
In the process of double mutagenesis, drug-targeted organisms are chemically
mutagenized, selected for under drug pressure, then mutagenized a second time and
selected for under still higher concentrations of experimental compound. This process is
designed to take advantage of a trait in observed in microbes with high-antimicrobial
resistance: a single mutation in the drug target may only induce low levels of resistance
where subsequent mutations may confer high levels of resistance. Thus, a double
mutagenesis is specifically designed to induce and select for single mutations in the drugtargeted gene with the first chemical mutagenesis then induce subsequent mutations in
the gene with the second chemical mutagenesis.
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In this work, the ubiquitous parasite Toxoplasma gondii was utilized. T. gondii
makes an ideal target for drug development because it infects nearly one third of the
world’s population, causes devastation to pregnant woman and the immunocompromised,
and there is currently no cure for the chronic stage [4,5,6]. Additionally, the current
treatments for toxoplasmosis, pyrimethamine and sulfadiazine (Figure 1), are toxic to the
host and, thus, the development of tolerable treatments is imperative [7]. Furthermore, the
genetic similarities between T. gondii and the causative agent of malaria, Plasmodium
falciparum, result in drugs effective against one of these pathogenic parasites often being
effective against the other [8,9].
To test the efficacy of double mutagenesis, we utilized the folate-pathwayinhibitor pyrimethamine as it has a known drug target. Thus, after performing double
mutagenesis, we were able to examine the accuracy of double mutagenesis by comparing
the experimentally identified drug target to the known target. We then used mutagenesis
to determine the drug target of the antioxoplasma compound, SW33. Following four
separate mutagenesis experiments, we observed that double mutagenesis was unable to
effectively confer resistance to SW33 in T. gondii. These results potentially suggest the
drug target of SW33 is unable to function when mutations are introduced. This could
indicate a drug target that is encoded in the apicoplast genome, as single mutations in
these genes result in nonviable parasites [10]. Additionally, SW33 may function as an
ionophore as previous works have demonstrated that mutagenesis is an ineffective tool
for identifying their MOA [10]. Future experiments will need to be performed in order to
test for the possibility of an apicoplast drug target and ionophore functions. Because
apicioplasts are unique to apicomplexans, the potential for SW33 to target this plastid
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would make it a promising drug for clinical use as it would be nontoxic to humans, thus
giving it an advantage over current treatments.

Figure 1

B

A

Pyrimethamine

Sulfadiazine

Figure 1: Structures of Pyrimethamine and Sulfadiazine
The current treatments for toxoplasmosis, sulfadiazine and pyrimethamine, both have affinity for human proteins
and are therefore toxic. A) Pyrimethamine is the current treatment for acute toxoplasmosis. It functions by
targeting DHFR which inhibits the folate pathway and pyrimethamine synthesis. B) Sulfadiazine also targets the
folate pathway.
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Materials and Methods
Parasites and media
T. gondii parasites were maintained through serial passage in human foreskin fibroblasts
(HFF) using DMEM media supplemented with 10% bovine calf serum as previously
described [11]. All parasite strains are derived from Type 1 RH T. gondii strain isolated
from a patient in 1939 [12]. Conditioned media was generated by infecting 175 cm2
flasks confluent with HFF with 7mL of media confluent with RH parasites.

Plaque Assays
Plaque assays were performed as previously described [13]. Briefly, 10 flasks containing
confluent HFF cells infected with T. gondii were cultured in 25 cm2 flasks. Nine of the
flasks were treated with varying concentrations of N-ethyl-N-nitrosurea (ENU) (1.25
mM, 2.5 mM, 5 mM), Ethylmethane sulfonate (EMS) (8mM, 10mM, 12mM), and a
combination of both EMS and ENU, respectively (6mM/3mM, 4mM/2mM, 2mM/1mM)
for four hours while the 10nth flask acted as an untreated control. Media was removed
and the monolayer was rinsed 3x with 1x PBS. The monolayer was then scraped,
homogenized, and syringe filtered. 1000 parasites from each flask were transferred to
new flasks. After 1 week, plaques were counted and percent death was determined.

Double Chemical Mutagenesis
Chemical mutagenesis was performed using both pyrimethamine and SW33, separately,
as previously described [13]. Briefly, a mixture of EMS (5mM) and ENU (3.5mM) were
added to 11 175 cm2 flasks confluent with RH strain parasites. Following 4 hours of
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incubation, the media was removed and the monolayer was rinsed 3x with 1x PBS. The
monolayer was then scraped, homogenized, syringe filtered, and passed to 175 cm2 flasks
confluent with HFF. After 24 hours, the flasks were then treated with 3.2µM, 4.26µM,
6.39µM 10.65µM, and 21.3µM of experimental compound SW33 or pyrimethamine.
Following four days of treatment, the monolayers were homogenized, syringe filtered,
and passed to 25 cm2 flasks where treatment was continued for 10 days. Parasites viable
at the highest SW33 concentration were subjected to a second round of EMS and ENU
before selection under .26µM, 6.39µM 10.65µM, 21.3µM, 31.95µM SW33.

Clonal Isolation
Resistant parasites were clonally isolated using serial dilution in 96-well plates
containing conditioned DMEM media. Singular plaques were identified through
fluorescence microscopy. Following five days of plaque formation, contents of singleplaque wells were transferred to 25 cm2 flasks confluent with HFF.

Half-maximal inhibitory concentration (IC50) analysis
96-well plates confluent with HFF were infected with 2,000 parasites per well. Serial
dilutions of SW33 were administered two days after infection. IC50 concentrations were
determined to be the concentrations of SW33 that reduced fluorescence by 50% using
flasks containing 1% DMSO as control. The IC50 of SW33 was determined to be 2.13 µM
in previously unpublished works.
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Results
Pyrimethamine double-mutagenesis optimization
To test the efficacy of double mutagenesis, pyrimethamine was utilized as the
experimentally found drug target can be compared to the known drug target. Following
the first mutagenesis experiment, the most drug-resistant mutant was three times more
resistant (4.5 µM) than WT (1.5 µM). After a second round of mutagenesis, the most
resistant mutant exhibited eight times more resistance than WT (figure 2). As DHFR is
the known target of pyrimethamine, the DHFR gene was PCR amplified in the resistant
mutant in order to compare the experimentally found drug target to the known drug
target. Interestingly, the sequenced DHFR showed no mutations.

Figure 2
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Figure 2: Observed Resistance of Parasites Before and After Double Mutagenesis
Double Mutagenesis introduced an 8-fold resistance to pyrimethamine compared to WT.
However, Sanger Sequencing of the DHFR of the most resistant clone showed no mutations.
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Figure 3
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Figure 3: Percent death caused by EMS and ENU
Plaque assays were performed using various concentrations of EMS, ENU, and a
combination of both EMS and ENU. A combination of EMS and ENU was chosen
at 5mM/2.5mM, respectively, as the concentrations that yielded 90% death. For
the mutagenesis using solely EMS, a concentration of 10mM was chosen.
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SW33 double mutagenesis
ENU and EMS are often used in chemical mutagenesis due to their ability to induce a
controlled amount of single nucleotide variances (SNVs)[13]. However, both mutagens
have distinct mutagenic profiles [13]. Thus, EMS and ENU were administered
concurrently, in order to induce a wide range of distinct mutations. Plaque assays using
both ENU and EMS indicate that 5mM EMS with 2.5mM ENU induce 90% killing as
determined using a best fit line (figure 3). This is the percent killing recommended to
induce one SNV per million base pairs as previously demonstrated [13]. Double chemical
mutagenesis was performed four separate times and drug selection above 4.26µM
consistently killed all parasites. In previous mutagenesis experiments, resistant parasites
were able to be maintained under constant drug selection above 50x IC50 [13]. Following
mutagenesis, SW33 concentrations over 3.2 µM (1.5x IC50) decimated the mutant
parasite populations. This unique result indicates that resistance may be difficult or
impossible to induce. A single flask of mutant parasites (population D) was able to be
maintained at 4.26 µM (2x IC50) after being treated for fourteen days with SW33,
followed by removal of drug treatment for approximately thirty days, then resumed
treatment with SW33.
After four double chemical mutageneses, there were four distinct parasite
populations viable at 3.2µM SW33 and a single population viable at 4.2µM (population
group D, Table 1). Clonal isolation was performed, and three clones were isolated from
each population resulting in fifteen clonal isolates. Half-maximal inhibitory
concentrations were derived for eight of the fifteen clonal isolates (table 1). Although
only low levels of resistance was observed, we are currently isolating DNA and sending
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samples to NGS. The next procedure will be to perform bioinformatics analysis on the
raw NGS data.

Figure 4
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Figure 4: Induced Resistance to SW33
While mutagenesis was able to induce mutations that conferred resistance to SW33, only 1.76x
resistance was observed. This unique result may be indicative of an apicoplast-gene target or
ionophore activity.
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Discussion
The pyrimethamine optimization yielded eight times more resistance than WT
parasite but no mutations were found in the DHFR. While this result is interesting,
limited funds hindered our ability to further examine the genome using NGS . However,
future experiments may include the examination of these parasites, as their resistance to
pyrimethamine through other means besides DHFR mutations may provide insight into
the potential for the development of clinical resistance in a similar fashion. Despite an not
finding the correct target, we believe double mutagenesis has viability for determining
MOA as high resistance was induced and future double mutageneses will include the
isolation of several clonal isolates with which to compare mutations. Sequencing multiple
clonal isolates and comparing their mutations will greatly improve the likelihood of
correctly identifying the drug target.
Given the lack of concurrent EMS and ENU applications in the literature, a
concentration that resulted in 90% killing was used in order to induce one SNV per
megabase (approximately 70 mutations per parasite). The results of the plaque assays
indicate that 5mM EMS and 2.5mM ENU lead to 90% death, as determined using a best
fit line (Figure 2). Because this concurrent treatment has never been administered, it is
unclear whether these concentrations induce one SNV per megabase; further sequencing
results are needed. There is a possibility that using both EMS and ENU simultaneously
leads to deleterious outcomes not present when used separately. Current SW33
mutagenesis experiments are being performed with EMS (no ENU) in order to address
this concern.
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Despite four separate double mutagenesis experiments, the most resistant clonal
isolate was just 1.76x more resistant than WT. Population D was able to remain viable at
the highest SW33 treatment, 2x IC50 concentrations. Interestingly, isolates from
population group D do not show the highest resistance. Low levels of resistance may be
the result of the drug target being an essential gene that cannot be mutated. This is
characteristic of genes encoding in the apicoplast as they are unable to be mutated and
still produce viable parasites [14]. Thus, there is a possibility that the drug target is a
protein synthesized in the apicoplast. This would be ideal as apicoplasts are unique to
apicomplexans and therefore SW33 would likely be nontoxic to humans. If the drug
target of SW33 is an essential gene whose mutations invariably cause parasite death, it is
unlikely that mutagenesis will lead to the elucidation of the mechanism of action. The
exception to this would be if mutations caused changes in gene expression, as
upregulation of the drug target would result in observed resistance.
While these results are not ideal in terms of robustly elucidating mechanism of
resistance, they may imply a potential difficulty or inability of the T. gondii to gain
resistance to SW33. If true, this would make SW33 a strong candidate for clinical use.
Further experiments should include the use of double mutagenesis on Plasmodium
falciparum using SW33. Although double chemical mutagenesis is proving unsuccessful
with SW33, it may still be a valuable lab technique. Mutagenesis can not only be used to
find drug targets but can provide valuable information into the ease of which an organism
may develop antimicrobial resistance to a specific drug. This information can then be
used as a metric to determine the best drugs for clinical trials as the drugs which parasites
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have the most difficulty building resistance to would potentially be the best drugs for
clinical use.
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